-
-
Humanized model of the immune system
-
iHuPBMC-T
-
iHuPBMC-NK
-
iHuPBMC-B
-
PBMC-LT
-
CD34+ HSC
-
Winn model
-
iHuPBMC-MHC/KO
-
iHuPBMC-OncVax
-
PBMC mixed inoculation model
more -
-
In vivo tumor experimental platform
-
CDX
-
iHuPDX
-
Non-GLP Toxicology
-
PK/PD
-
Brain in situ model
-
Other in situ models
-
Hematologic tumor model system inoculation
-
Creation of high interstitial tumor models
more -
-
In vitro killing experiment platform
-
Immune co-culture killing model
-
CDC
-
In vitro killing experiment platform
-
IC50
-
PDC High-Throughput In Vitro Pharmacodynamics
-
3D organoids
-
ADCC
-
T cell-mediated killing experiment
more -
-
Mouse-derived immune system model
more -
Tumor vaccine
more -
Cell therapy
more -
In vitro testing platform
more -
Non-GLP Toxicology Platform
more -
Non-tumor model and drug efficacy evaluation platform
-
Systematic Vaccination Model
-
Non-tumor model and drug efficacy evaluation platform
-
Skin injury model
-
Stroke model
-
Liver fibrosis model
-
Diabetes model
-
Gouty Arthritis (GA) Model
-
Pulmonary fibrosis model
-
Systemic lupus erythematosus (SLE) model
-
Inflammatory Bowel Disease (IBD) model
-
Rheumatoid Arthritis (RA) Model
more -
-
-
-
PDX model
-
PDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
CDX model
-
CDX model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Human breast cancer
-
Esophageal cancer in humans
-
Human gastric cancer
-
Colorectal cancer
-
Human liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Human pancreatic cancer
-
Human kidney cancer
-
Human Bladder Cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer in women
-
Human Ovarian Cancer
-
Human skin cancer
-
sarcoma
-
Human Nervous System Cancer
-
Embryonal carcinoma
-
Human Lymphoma
-
Human leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other people
more -
-
Homogeneous Model
-
Homogeneous Model
-
Head and neck cancer
-
Eye cancer
-
Lung cancer
-
Breast cancer
-
Stomach cancer
-
Liver cancer
-
Bile duct cancer
-
Gallbladder cancer
-
Pancreatic cancer
-
Kidney cancer
-
Bladder cancer
-
Ureteral cancer
-
Prostate cancer
-
Uterine cancer
-
Cervical cancer
-
Ovarian cancer
-
Esophageal cancer
-
Skin cancer
-
sarcoma
-
Nervous System Cancer
-
Embryonal carcinoma
-
Lymphoma
-
Leukemia
-
Multiple Myeloma
-
Adrenal gland
-
Mesothelioma
-
Other
-
Colorectal cancer
more -
-
News Center
——
InnoModels Biotechnology iHuPDX Model: A New Milestone in Personalized Medicine
Author:
InnoModels
Release time:
2024-05-06
With the deepening of medical research, traditional cancer research and treatment methods can no longer meet the growing demand for individualization. Against this backdrop, the iHuPDX (Individualized Human Patient-Derived Xenograft) model of InnoModels Biotechnology has emerged, bringing a new perspective and solution to the field of cancer research and treatment.
The iHuPDX model is a xenograft technology based on individual patient's tumor cells, which forms individualized transplanted tumors by collecting patient's cancer tissue samples and transplanting them into animals such as mice. This technology can more realistically simulate the tumor environment in the patient's body, providing important support for precision medicine.
First, the iHuPDX model is highly individualized. Each patient's tumor has its own unique biological characteristics and heterogeneity, and the iHuPDX model is able to preserve these original features, enabling researchers to gain a more comprehensive understanding of a patient's tumor characteristics. This highly individualized model provides an important experimental tool for precision medicine and helps develop more personalized treatment plans.
Second, the iHuPDX model can be used to predict drug response. Due to the highly individualized nature of the model, researchers can use the iHuPDX model to test the response of different drugs to a specific patient's tumor. This provides a powerful tool for personalized treatment plan development and is expected to improve treatment success rates. Through drug sensitivity experiments, doctors can predict a patient's response to different drugs so that they can choose the most appropriate treatment plan for the patient.

In addition, the iHuPDX model provides a new perspective for cancer research. Through in-depth study of tumor heterogeneity among different patients, researchers can better understand the diversity and complexity of cancer. This provides important information for the development of individualized therapeutic strategies and helps to advance cancer treatment.
The iHuPDX model from InnoModels Biotechnology has other advantages. First, it retains the heterogeneity of the original tumor tissue, making the model closer to the actual patient. Second, the model has good stability and growth rate, providing a reliable experimental platform for drug development and efficacy assessment. Finally, InnoModels Biotechnology has a stable platform of humanized immune system mouse model (HIS) and human tumor xenograft platform (PDX), which provides comprehensive technical support for tumor and tumor immunopharmacodynamics research.
In conclusion, the iHuPDX model from InnoModels Biotechnology has revolutionized the field of cancer research and treatment. It establishes a highly individualized disease model based on individual patient's tumor cells, providing an important experimental tool for precision medicine. By predicting drug response and studying tumor heterogeneity in depth, the iHuPDX model is expected to increase the success rate of treatment and advance cancer therapy. The continuous innovation and efforts of InnoModels Biotechnology in the field of personalized medicine provide more precise and personalized solutions for medical research and drug development, and bring more hope and possibilities to tumor patients.
Previous Page
InnoModels Biotechnology (Beijing) Co., Ltd.
-
TEL: +86 15711355061
-
E-mail: xuyl@imodels.tech
-
Address: Building 14, No. 79 West Shuangying Road, Changping District, Beijing
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
COOKIES
Our website uses cookies and similar technologies to personalize the advertising shown to you and to help you get the best experience on our website. For more information, see our Privacy & Cookie Policy
These cookies are necessary for basic functions such as payment. Standard cookies cannot be turned off and do not store any of your information.
These cookies collect information, such as how many people are using our site or which pages are popular, to help us improve the customer experience. Turning these cookies off will mean we can't collect information to improve your experience.
These cookies enable the website to provide enhanced functionality and personalization. They may be set by us or by third-party providers whose services we have added to our pages. If you do not allow these cookies, some or all of these services may not function properly.
These cookies help us understand what you are interested in so that we can show you relevant advertising on other websites. Turning these cookies off will mean we are unable to show you any personalized advertising.
InnoModels Biotechnology (Beijing) Co., Ltd